/
We may be required to suspend or discontinue clinical trials due to unexpected side effects or other safety risks that could preclude approval of our product candidates. For example, we may voluntarily suspend or terminate our clinical trials if at any time we believe that they present an unacceptable risk to the clinical trial patients.
The business is unprofitable at the operating level (-1113.98% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 2511.6% YoY with margins expanding 24397.6pp.
Negative free cash flow of -$11M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$1M
▲ +2511.6% YoY
Net Income (TTM)
-$12M
▼ -26.7% YoY
Op. Margin
-864.27%
▲ +24397.6pp YoY
ROIC
-112.03%
▲ +174.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$11M
▼ -20.1% YoY
Op. Cash Flow (TTM)
-$11M
▼ -20.3% YoY
Net Debt
-$12M
Net Cash Position
Cash & Equiv.
$12M
Continue Research